Dogwood Therapeutics, Inc.
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
DWTX$1.28+23.1%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Selected Financial Data
Selected Financial Data
(unaudited)
| Condensed Consolidated Statements of Operations Data · · Three Months EndedSeptember 30, · · · Nine Months EndedSeptember 30, · | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · 2026 · · · 2025 · · · 2026 · · · 2025 · | ||||||||||||||||
| Licensing revenue | | $100,000 | | | $— | | | $100,000 | | | $— | | ||||
| CVR expense | | | 88,104 | | | | — | | | | 88,104 | | | | — | |
| Gross profit | | | 11,896 | | | | — | | | | 11,896 | | | | — | |
| Operating expenses: | | | | | | | | | | | | | | | | |
| Research and development | | | 3,352,977 | | | | 14,521,342 | | | | 9,269,275 | | | | 19,528,283 | |
| General and administrative | | | 1,576,219 | | | | 1,287,783 | | | | 5,608,915 | | | | 4,633,883 | |
| IPR&D impairment | | | — | | | | — | | | | 9,190,897 | | | | — | |
| Total operating expenses | | | 4,929,196 | | | | 15,809,125 | | | | 24,069,087 | | | | 24,162,166 | |
| Loss from operations | | | (4,917,300) | | | (15,809,125) | | | (24,057,191) | | | (24,162,166) | ||||
| Other income (expense): | | | | | | | | | | | | | | | | |
| Sublease income | | | 27,241 | | | | — | | | | 64,138 | | | | — | |
| Loss on debt conversion with related party | | | — | | | | — | | | | — | | | | (6,134,120) | |
| Interest income, net | | | 42,035 | | | | 80,582 | | | | 185,734 | | | | 44,871 | |
| Exchange loss, net | | | (35,757) | | | (17,509) | | | (72,186) | | | (36,251) | ||||
| Total other income (expense), net | | | 33,519 | | | | 63,073 | | | | 177,686 | | | | (6,125,500) | |
| Loss before income taxes | | | (4,883,781) | | | (15,746,052) | | | (23,879,505) | | | (30,287,666) | ||||
| Deferred income tax benefit (expense) | | | 839 | | | | 1,436 | | | | 2,480,340 | | | | (189,255) | |
| Net Loss | | | (4,882,942) | | | (15,744,616) | | | (21,399,165) | | | (30,476,921) | ||||
| Accrual of paid-in-kind dividends on Series A non-voting convertible preferred stock | | | — | | | | — | | | | — | | | | (1,256,662) | |
| Net loss attributable to common stockholders | | $(4,882,942) | | $(15,744,616) | | $(21,399,165) | | $(31,733,583) | ||||||||
| Net loss per share of common stock — basic and diluted | | $(0.14) | | $(8.20) | | $(0.63) | | $(18.02) | ||||||||
| Weighted average shares outstanding — basic and diluted | | | 34,129,553 | | | | 1,919,433 | | | | 33,936,760 | | | | 1,761,237 | |
| | | | | | | | | | | | | | | | | |
| Condensed Consolidated Balance Sheet Data · September 30, · · · December 31, · | |||||||
|---|---|---|---|---|---|---|---|
| · 2026 · · · 2025 · | |||||||
| | | | | | | | |
| Cash and cash equivalents | $4,948,266 | | | $6,524,744 | | ||
| Total assets | | 75,608,219 | | | | 90,171,237 | |
| Total liabilities | | 11,475,000 | | | | 15,274,370 | |
| Total stockholders’ equity | | 64,133,219 | | | | 74,896,867 | |
Source: Dogwood Therapeutics, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.